Varda Space Industries has raised US$187 million in its series C funding round, increasing its total funding to US$329 million.

The round was led by Natural Capital and Shrug Capital, with participation from Founders Fund, Khosla Ventures, Caffeinated Capital, Lux Capital, and others.

The company has completed three orbital missions since 2023 and plans two more this year, including the ongoing W-4 mission.

Varda runs the first commercial microgravity labs outside the International Space Station (ISS), enabling unique pharmaceutical formulations not possible on Earth.

It also operates a hypersonic testbed for government partners, testing tech like thermal shields and communication systems at Mach 25, 2025.

The company has expanded its infrastructure by opening a 10,000-square-foot laboratory in El Segundo, California, and a new office in Huntsville, Alabama.

The latest funding will enhance mission frequency and support the development of its pharmaceutical lab.

This funding marks a significant step for Varda as it continues to establish its capabilities in orbital reentry and microgravity manufacturing.

🔗 Source: PR Newswire

🧠 Food for thought

1️⃣ Space-based pharmaceutical manufacturing represents a rapidly growing market opportunity

The space-based biopharmaceuticals market that Varda is targeting is projected to grow from $5.14 billion in 2024 to $9.41 billion by 2029, representing a compound annual growth rate of 13.2% 1.

This growth is driven by the increased demand for novel drug development approaches and significant investments in space biotech infrastructure that make manufacturing more feasible 1.

Industry analysts have identified over 90 companies now operating in the space biotech sector, with potential revenue growth of $3-4 billion expected from collaborations between pharmaceutical companies and space biotech firms 2.

Varda’s focus on monoclonal antibodies is particularly strategic, as this segment alone represents a $210 billion market opportunity according to the original article, making it one of the most valuable potential applications for space manufacturing.

The substantial funding round reflects investor confidence in the commercial viability of space-based manufacturing, which has evolved from purely experimental research to a potential industrial process with clear pharmaceutical applications.